Medmonitor

An up-to-date timeline of U.S. Food and Drug Administration (FDA) approvals that could potentially impact workers' compensation. These include new drug and indication approvals, new dosages or formulations of existing products, and generics introduced to the market. Click through the interactive timeline below, or select the comprehensive list view.

← Back to Medmonitor

Medication Type: Mental Health

Trintellix^® (vortioxetine) tablets

Approval Date: Sep 2021

Note: First-Time Generic

Indicated for the treatment of major depressive disorder (MDD)

Loreev XR (lorazepam) extended release capsules

Approval Date: Sep 2021

Note: New Product

For the treatment of anxiety disorders in adults receiving stable, evenly divided, three times daily dosing with lorazepam tablets

LYBALVI^™ (OLANZAPINE AND SAMIDORPHAN) TABLETS FOR ORAL USE

Approval Date: May 2021

Note: New Product

A combination antipsychotic and opioid antagonist for the treatment of schizophrenia, bipolar I disorder

« Previous 1 2

Medication Name

Approval Date

Category

Description

Trintellix^® (vortioxetine) tablets

Sep 2021

Indicated for the treatment of major depressive disorder (MDD)

Note: First-Time Generic

Loreev XR (lorazepam) extended release capsules

Sep 2021

For the treatment of anxiety disorders in adults receiving stable, evenly divided, three times daily dosing with lorazepam tablets

Note: New Product

LYBALVI^™ (OLANZAPINE AND SAMIDORPHAN) TABLETS FOR ORAL USE

May 2021

A combination antipsychotic and opioid antagonist for the treatment of schizophrenia, bipolar I disorder

Note: New Product

« Previous 1 2

Workers' Comp Property and Casualty PBM
Expires 01/01/2028